Drug intelligence / Profile preview

TLN-372

Development stage: Phase 1
Lead developer: Treeline Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**TLN-372** is a small molecule pan-KRAS inhibitor developed by Treeline Biosciences for advanced KRAS-mutant solid tumors. It employs novel chemistry to achieve deep and continuous inhibition of the KRAS pathway across multiple KRAS mutations, addressing unmet needs beyond G12C-specific therapies. Currently in Phase 1 trials evaluating safety, pharmacokinetics, and anti-tumor activity as monotherapy and in combinations (e.g., with cetuximab or pembrolizumab).[1][2][3][7][10][16]

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on TLN-372.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLN-372.

Explore the full profile